BRAF

(redirected from B-Raf)

BRAF

A gene on chromsome 7q34 that encodes a protein of the raf/mil family of serine/threonine protein kinases, which plays a role in regulating the MAP kinase/ERKs-signalling pathway, affecting cell division, differentiation and secretion.

Molecular pathology
BRAF mutations are associated with cardiofaciocutaneous syndrome, which is characterised by heart defects, mental retardation and a distinctive facial appearance. Acquired BRAF mutations have been linked to non-Hodgkin lymphoma, colorectal cancer, melanoma, thyroid carcinoma, non-small cell lung carcinoma and adenocarcinoma of lung.
References in periodicals archive ?
Pre-clinical data presented at the conference demonstrated the broad applicability of Celator's hydrophobic prodrug nanoparticle (HPN) delivery technology to MTAs from diverse classes, including inhibitors of MEK, Akt, HSP90, B-Raf and FGFR.
The decision is conditional upon the divestment of two of Novartis' cancer treatments: LGX818, a B-Raf inhibitor, and MEK162, a MEK inhibitor.
Additionally, clinical molecular tests for serine/threonine-protein kinase B-Raf (BRAF) and GTPase Kras (KRAS) gene biomarkers, as well as for epidermal growth factor receptor (EGFR), are driving the demand for the FFPE sample preps.
Novel therapies that target the root causes of cancer (such as B-Raf, Bcr-Abl, EGFR and HER2), when given to the 'right' patients harboring those defects, clearly demonstrate substantial benefits compared with older chemo and radiation treatments--so much so, that biotech and pharma companies are now fully bought into this concept, even if it means smaller patient populations.
Firstly, a study of a B-raf inhibitor in patients with advanced
They analyzed human cancer cells, searching for ones that exhibit B-RAF mutations as well as elevated COT levels.
FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKC, B-Raf and S6K2.
Most of these somatic variations occur in the kinase domain of B-Raf encoded by exons 11 and 15 of the gene (6,10) and are thought to act by directly increasing the constitutive kinase activity toward its downstream targets MAPKK (mitogen-activated protein kinase kinase) and MAPK (mitogen-activated protein kinase), although other indirect mechanisms exist (11,12).
Mark Kelley, MD, MMHC, FACS, Vanderbilt-Ingram Cancer Center, "Biomarkers of Response and Resistance to Sequential B-RAF and MEK Targeted Therapy in a Pre-Surgical Model of Advanced, Operable Melanoma"
Recently approved compounds demonstrate significant antitumor activities and survival benefits for B-Raf and Mek inhibitors.
163 for award of providing two-year service, with option to extend for a further two years, a system for the development of molecular tests in the K-RAS, B-RAF and EGFR Pharmacogenomics, for the needs of the Hospital -University of Cagliari.
As part of the latest research, scientists in California developed a drug to block the effects of a specific gene mutation, B-RAF, linked to malignant melanoma - one of the deadliest cancers.